Cargando…
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474542/ https://www.ncbi.nlm.nih.gov/pubmed/36104315 http://dx.doi.org/10.1038/s41467-022-32797-w |
_version_ | 1784789742305411072 |
---|---|
author | Antonschmidt, Leif Matthes, Dirk Dervişoğlu, Rıza Frieg, Benedikt Dienemann, Christian Leonov, Andrei Nimerovsky, Evgeny Sant, Vrinda Ryazanov, Sergey Giese, Armin Schröder, Gunnar F. Becker, Stefan de Groot, Bert L. Griesinger, Christian Andreas, Loren B. |
author_facet | Antonschmidt, Leif Matthes, Dirk Dervişoğlu, Rıza Frieg, Benedikt Dienemann, Christian Leonov, Andrei Nimerovsky, Evgeny Sant, Vrinda Ryazanov, Sergey Giese, Armin Schröder, Gunnar F. Becker, Stefan de Groot, Bert L. Griesinger, Christian Andreas, Loren B. |
author_sort | Antonschmidt, Leif |
collection | PubMed |
description | Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synuclein fibrils and anle138b, a clinical drug candidate for disease modifying therapy in neurodegeneration and a promising scaffold for positron emission tomography tracer design. We used nuclear magnetic resonance spectroscopy and the cryogenic electron microscopy structure of α-synuclein fibrils grown in the presence of lipids to locate anle138b within a cavity formed between two β-strands. We explored and quantified multiple binding modes of the compound in detail using molecular dynamics simulations. Our results reveal stable polar interactions between anle138b and backbone moieties inside the tubular cavity of the fibrils. Such cavities are common in other fibril structures as well. |
format | Online Article Text |
id | pubmed-9474542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94745422022-09-16 The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils Antonschmidt, Leif Matthes, Dirk Dervişoğlu, Rıza Frieg, Benedikt Dienemann, Christian Leonov, Andrei Nimerovsky, Evgeny Sant, Vrinda Ryazanov, Sergey Giese, Armin Schröder, Gunnar F. Becker, Stefan de Groot, Bert L. Griesinger, Christian Andreas, Loren B. Nat Commun Article Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative diseases. Atomic resolution of small molecule binding to such pathological protein aggregates is of interest for the development of therapeutics and diagnostics. Here we investigate the interaction between α-synuclein fibrils and anle138b, a clinical drug candidate for disease modifying therapy in neurodegeneration and a promising scaffold for positron emission tomography tracer design. We used nuclear magnetic resonance spectroscopy and the cryogenic electron microscopy structure of α-synuclein fibrils grown in the presence of lipids to locate anle138b within a cavity formed between two β-strands. We explored and quantified multiple binding modes of the compound in detail using molecular dynamics simulations. Our results reveal stable polar interactions between anle138b and backbone moieties inside the tubular cavity of the fibrils. Such cavities are common in other fibril structures as well. Nature Publishing Group UK 2022-09-14 /pmc/articles/PMC9474542/ /pubmed/36104315 http://dx.doi.org/10.1038/s41467-022-32797-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Antonschmidt, Leif Matthes, Dirk Dervişoğlu, Rıza Frieg, Benedikt Dienemann, Christian Leonov, Andrei Nimerovsky, Evgeny Sant, Vrinda Ryazanov, Sergey Giese, Armin Schröder, Gunnar F. Becker, Stefan de Groot, Bert L. Griesinger, Christian Andreas, Loren B. The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title | The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title_full | The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title_fullStr | The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title_full_unstemmed | The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title_short | The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
title_sort | clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474542/ https://www.ncbi.nlm.nih.gov/pubmed/36104315 http://dx.doi.org/10.1038/s41467-022-32797-w |
work_keys_str_mv | AT antonschmidtleif theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT matthesdirk theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT dervisoglurıza theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT friegbenedikt theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT dienemannchristian theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT leonovandrei theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT nimerovskyevgeny theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT santvrinda theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT ryazanovsergey theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT giesearmin theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT schrodergunnarf theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT beckerstefan theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT degrootbertl theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT griesingerchristian theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT andreaslorenb theclinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT antonschmidtleif clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT matthesdirk clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT dervisoglurıza clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT friegbenedikt clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT dienemannchristian clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT leonovandrei clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT nimerovskyevgeny clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT santvrinda clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT ryazanovsergey clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT giesearmin clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT schrodergunnarf clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT beckerstefan clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT degrootbertl clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT griesingerchristian clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils AT andreaslorenb clinicaldrugcandidateanle138bbindsinacavityoflipidicasynucleinfibrils |